Oncotarget

Research Papers:

Development of gene expression-based risk score in cytogenetically normal acute myeloid leukemia patients

Elias Bou Samra, Bernard Klein, Thérèse Commes and Jerome Moreaux _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2012; 3:824-832. https://doi.org/10.18632/oncotarget.571

Metrics: PDF 1512 views  |   HTML 1403 views  |   ?  


Abstract

Elias Bou Samra1,2, Bernard Klein2,3,4, Thérèse Commes1,2, Jérôme Moreaux2,4

1 Groupe d’études des transcriptomes, Université MONTPELLIER 2;

2 INSERM, U1040, Montpellier, F-34197 France;

3 CHU Montpellier, Institute of Research in Biotherapy, Montpellier, FRANCE;

4 Université MONTPELLIER1, UFR Médecine, Montpellier, France;

Correspondence:

Jérôme Moreaux, email:

Keywords: gene expression-based risk score, cytogenetically normal-acute myeloid leukemia, prognostic gene signature, EVI1 expression

Received: July 25, 2012, Accepted: August 17, 2012, Published: August 18, 2012

Abstract

Patients with normal karyotype represent the single largest cytogenetic group of acute myeloid leukemia (AML), with highly heterogeneous clinical and molecular characteristics. In this study, we sought to determine new prognostic biomarkers in cytogenetically normal (CN)-AML patients. A gene expression (GE)-based risk score was built, summing up the prognostic value of 22 genes whose expression is associated with a bad prognosis in a training cohort of 163 patients. GE-based risk score allowed identifying a high-risk group of patients (53.4%) in two independent cohorts of CN-AML patients. GE-based risk score and EVI1 gene expression remained independent prognostic factors using multivariate Cox analyses. Combining GE-based risk score with EVI1 gene expression allowed the identification of three clinically different groups of patients in two independent cohorts of CN-AML patients. Thus, GE-based risk score is powerful to predict clinical outcome for CN-AML patients and may provide potential therapeutic advances.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 571